Parkinson's disease.
Barboi
A C
AC
Department of Neurological Science, Rush University/Rush Presbyterian/St. Luke's Medical Center, Chicago, Illinois, USA.
Goetz
C G
CG
D000547:Amantadine / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D002230:Carbidopa / Q000097:blood / Q000627:therapeutic use; D004298:Dopamine / Q000096:biosynthesis; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004347:Drug Interactions; D006801:Humans; D007980:Levodopa / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced
D000928:Antidepressive Agents; D000959:Antihypertensive Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D018491:Dopamine Agonists; D007980:Levodopa; D000547:Amantadine; D002230:Carbidopa; D004298:Dopamine